Evidence map›Paper›PMID 35681564›Full record

ArticleCancers2022

Inhibition of HDAC and Signal Transduction Pathways Induces Tight Junctions and Promotes Differentiation in p63-Positive Salivary Duct Adenocarcinoma.

Masaya Nakano, Kizuku Ohwada, Yuma Shindo, Takumi Konno, Takayuki Kohno, Shin Kikuchi, Mitsuhiro Tsujiwaki, Daichi Ishii, Soshi Nishida, Takuya Kakuki and 6 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Reciprocity between p63 and p21 via TNFα/NF-κB signaling in p63-positive salivary duct adenocarcinoma cell.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Masaya NakanoDepartment of Cell Science, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan.
Kizuku OhwadaDepartment of Cell Science, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan.
Yuma ShindoDepartment of Cell Science, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan.
Takumi KonnoDepartment of Cell Science, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan.ORCID 0000-0002-9339-3864
Takayuki KohnoDepartment of Cell Science, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan.ORCID 0000-0002-1782-3578
Shin KikuchiDepartment of Anatomy, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan.
Mitsuhiro TsujiwakiDepartment of Pathology, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan.
Daichi IshiiDepartment of Cell Science, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan.
Soshi NishidaDepartment of Cell Science, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan.
Takuya KakukiDepartment of Otolaryngology, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan.
Kazufumi ObataDepartment of Otolaryngology, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan.
Ryo MiyataDepartment of Otolaryngology, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan.
Makoto KuroseDepartment of Otolaryngology, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan.
Atsushi KondohDepartment of Otolaryngology, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan.
Kenichi TakanoDepartment of Otolaryngology, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan.
Takashi KojimaDepartment of Cell Science, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan.ORCID 0000-0002-6346-4588
Sapporo Medical University · JP

Funding

Kenichi Takano 21K09610Ryo Miyata 19K18777Takashi Kojima 19K07464
6 · The paper itself

Abstract

backgroundThe p53 family p63 is essential for the proliferation and differentiation of various epithelial basal cells. It is overexpressed in several cancers, including salivary gland neoplasia. Histone deacetylases (HDACs) are thought to play a crucial role in carcinogenesis, and HDAC inhibitors downregulate p63 expression in cancers.

methodsIn the present study, to investigate the roles and regulation of p63 in salivary duct adenocarcinoma (SDC), human SDC cell line A253 was transfected with siRNA-p63 or treated with the HDAC inhibitors trichostatin A (TSA) and quisinostat (JNJ-26481585).

resultsIn a DNA array, the knockdown of p63 markedly induced mRNAs of the tight junction (TJ) proteins cingulin (CGN) and zonula occuludin-3 (ZO-3). The knockdown of p63 resulted in the recruitment of the TJ proteins, the angulin-1/lipolysis-stimulated lipoprotein receptor (LSR), occludin (OCLN), CGN, and ZO-3 at the membranes, preventing cell proliferation, and leading to increased cell metabolism. Treatment with HDAC inhibitors downregulated the expression of p63, induced TJ structures, recruited the TJ proteins, increased the epithelial barrier function, and prevented cell proliferation and migration.

conclusionsp63 is not only a diagnostic marker of salivary gland neoplasia, but it also promotes the malignancy. Inhibition of HDAC and signal transduction pathways is, therefore, useful in therapy for p63-positive SDC cells.

Indexed as

EW-7198HDAC inhibitorsp63salivary duct adenocarcinomaSP600125tight junctions

Identifiers

PMID35681564
PMCPMC9179926
OpenAlexW4281556224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.